Identification of Immunologic Mechanisms of Enhanced Ng Clearance Induced by Nm OMV-based Vaccines
Nm OMV 疫苗诱导 Ng 清除增强的免疫机制鉴定
基本信息
- 批准号:10362594
- 负责人:
- 金额:$ 21.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-26 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntibiotic ResistanceAntibodiesAntibody ResponseAntibody titer measurementAntigen PresentationAntigen TargetingAntigensAntimicrobial ResistanceB-LymphocytesCenters for Disease Control and Prevention (U.S.)Chlamydia trachomatisControl AnimalCubaDataDevelopment PlansEngineeringFDA approvedFemaleGenitalGenitaliaGonorrheaHumanImmuneImmune EvasionImmune responseImmunityImmunizationImmunologicsInfectionLongitudinal observational studyMass VaccinationsMembraneMucous MembraneMusNatural ImmunityNeisseriaNeisseria gonorrhoeaeNeisseria meningitidisNew ZealandNorwayOutcomePlayRecombinant ProteinsResearchRoleSerogroup B Neisseria meningitidisSerumSexual TransmissionSpecificitySurface AntigensT cell responseT-LymphocyteTestingTimeUpper respiratory tractVaccinatedVaccinationVaccinesVesiclebactericidebaseclinical developmentcross immunityepidemiology studygonorrhea vaccinemajor outer membrane proteinmouse modelpathogenpathogenic bacteriapreclinical developmentpreventreproductive tractresearch clinical testingresponsestemvaccine developmentvaccine-induced immunity
项目摘要
Abstract
Neisseria gonorrhoeae (Ng) is the most prevalent sexually transmitted bacterial pathogen globally, and
gonococcal antibiotic resistance continues to rise. Potentially untreatable gonorrhea is recognized as an urgent
threat by WHO and the US CDC. Gonococcal vaccine development is critical to help stem the spread of
antimicrobial resistant Ng. Because naturally-acquired infection does not result in immunity from subsequent
infection, immune responses required for protection from infection have never been definitively established for
N. gonorrhoeae. Recently, a vaccine has been developed for N. meningitidis (Nm) serogroup B, and mass
vaccination campaigns with this outer membrane vesicle (OMV)-containing vaccine have demonstrated
collateral reduction in gonorrhea rates. Nm-OMV vaccines also show protection in a mouse model of genital
Ng infection. For the first time,we have the opportunity to study both human and murine immune responses to
effective vaccines, and identify likely correlates of protection. Project 1 in the Gonorrhea Vaccine Cooperative
Research Center (GV CRC) will (1) determine whether murine humoral immune responses to Nm-OMV-
containing vaccines are important in protection from Ng infection; (2) identify murine cellular immune
mechanisms induced by Nm-OMV-containing vaccines that contribute to protection from Ng infection; and (3)
determine humoral and cellular immune responses to Ng antigens induced by Nm-OMV-containing vaccine in
humans. Defining immunologic mechanisms that provide protection from Ng infection is critical to advancing
Ng vaccine development.!We will engage with all 4 scientific cores of the GV CRC. Our studies will set the
stage for clinical evaluation of Nm-OMV vaccines for protection from Ng and will inform vaccine development
plans in other GV CRC projects.
摘要
淋病奈瑟菌(Ng)是全球最流行的性传播细菌病原体,
淋球菌对抗生素的抗药性继续上升。潜在的无法治愈的淋病被认为是一个紧迫的
世界卫生组织和美国CDC的威胁。淋球菌疫苗的开发对于帮助阻止
抗微生物Ng.因为自然获得性感染不会导致免疫力从随后的
尽管免疫系统中存在感染,但保护免受感染所需的免疫应答从未明确建立,
N.淋病最近,已经开发出了针对N.脑膜炎(Nm)血清群B和肿块
使用这种含有外膜囊泡(OMV)的疫苗的疫苗接种活动已经证明,
淋病发病率的间接降低。Nm-OMV疫苗也在生殖器感染的小鼠模型中显示出保护作用。
Ng感染。这是我们第一次有机会研究人类和小鼠对
有效的疫苗,并确定可能的保护相关性。淋病疫苗合作社项目1
研究中心(GV CRC)将(1)确定小鼠对Nm-OMV的体液免疫应答-
含有疫苗的疫苗在保护免受Ng感染方面是重要的;(2)鉴定小鼠细胞免疫
由含有Nm-OMV的疫苗诱导的有助于保护免受Ng感染的机制;以及(3)
确定由含Nm-OMV的疫苗诱导的对Ng抗原的体液和细胞免疫应答,
人类定义提供保护免受Ng感染的免疫机制对于促进Ng感染的发展至关重要。
疫苗研发!我们将与GV CRC的所有4个科学核心合作。我们的研究将为
Nm-OMV疫苗预防Ng的临床评价阶段,并将为疫苗开发提供信息
其他GV CRC项目的计划。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH A DUNCAN其他文献
JOSEPH A DUNCAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH A DUNCAN', 18)}}的其他基金
Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection
了解淋病奈瑟菌感染自然史的病原体和宿主决定因素
- 批准号:
10703733 - 财政年份:2023
- 资助金额:
$ 21.75万 - 项目类别:
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
4C-MenB 免疫预防实验性尿道淋病奈瑟菌感染的功效。
- 批准号:
10615898 - 财政年份:2021
- 资助金额:
$ 21.75万 - 项目类别:
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
4C-MenB 免疫预防实验性尿道淋病奈瑟菌感染的功效。
- 批准号:
10263478 - 财政年份:2021
- 资助金额:
$ 21.75万 - 项目类别:
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
4C-MenB 免疫预防实验性尿道淋病奈瑟菌感染的功效。
- 批准号:
10435532 - 财政年份:2021
- 资助金额:
$ 21.75万 - 项目类别:
Identification of Immunologic Mechanisms of Enhanced Ng Clearance Induced by Nm OMV-based Vaccines
Nm OMV 疫苗诱导 Ng 清除增强的免疫机制鉴定
- 批准号:
10588241 - 财政年份:2019
- 资助金额:
$ 21.75万 - 项目类别:
Regulation of the physiologic and pathologic activation of the NLRP3-inflammasome
NLRP3 炎症小体生理和病理激活的调节
- 批准号:
8456181 - 财政年份:2010
- 资助金额:
$ 21.75万 - 项目类别:
Regulation of the physiologic and pathologic activation of the NLRP3-inflammasome
NLRP3 炎症小体生理和病理激活的调节
- 批准号:
8646852 - 财政年份:2010
- 资助金额:
$ 21.75万 - 项目类别:
Regulation of the physiologic and pathologic activation of the NLRP3-inflammasome
NLRP3 炎症小体生理和病理激活的调节
- 批准号:
7992559 - 财政年份:2010
- 资助金额:
$ 21.75万 - 项目类别:
Regulation of the physiologic and pathologic activation of the NLRP3-inflammasome
NLRP3 炎症小体生理和病理激活的调节
- 批准号:
8443468 - 财政年份:2010
- 资助金额:
$ 21.75万 - 项目类别:
相似海外基金
Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
- 批准号:
EP/Y031067/1 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307222 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
- 批准号:
502587 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
- 批准号:
2307223 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
- 批准号:
MR/X009580/1 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
- 批准号:
2340818 - 财政年份:2024
- 资助金额:
$ 21.75万 - 项目类别:
Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
- 批准号:
480022 - 财政年份:2023
- 资助金额:
$ 21.75万 - 项目类别:
Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
- 批准号:
BB/X010473/1 - 财政年份:2023
- 资助金额:
$ 21.75万 - 项目类别:
Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
- 批准号:
10670613 - 财政年份:2023
- 资助金额:
$ 21.75万 - 项目类别:














{{item.name}}会员




